d Asia-Pacific Consensus Guidelines for Helicobacter pylori Infection. Journal of Gastroenterology and Hepatology, 24, 1587-1600.
http://dx.doi.org/10.1111/j.1440-1746.2009.05982.x

[8]   Mégraud, F. (2004) H. pylori Antibiotic Resistance: Prevalence, Importance and Advances in Testing. Gut, 53, 1374- 1384.
http://dx.doi.org/10.1136/gut.2003.022111

[9]   Fischbach, L. and Evans, E.L. (2007) Meta-Analysis: The Effect of Antibiotic Resistance Status on the Efficacy of Triple and Quadruple First-Line Therapies for Helicobacter pylori. Alimentary Pharmacology & Therapeutics, 26, 343-357.
http://dx.doi.org/10.1111/j.1365-2036.2007.03386.x

[10]   Fall, F., Diagne, A., Ndiaye, B., et al. (2011) Trithérapie par oméprazole, amoxicilline et clarithromycine dans la maladie ulcéreuse duodénale associée à Helicobacter pylori au Sénégal. Journal African d’Hépato-Gastroentérologie, 5, 28-32.

[11]   Assi, C., Ndah, K.J., Allah-Kouadio, E., et al. (2010) Prévalence de l’infection à Helicobacter pylori et lésions pré-cancéreuses du cancer gastrique chez les patients souffrant d’épigastralgies chroniques. Revue Africaine de Pathologie, 9, 25-31.

[12]   Werme, K., Bisseye, C., Ouedraogo, I., et al. (2015) Diagnostic moléculaire d’helicobacter pylori par PCR chez les patients en consultation gastroentérologique au Centre Médical Saint Camille de Ouagadougou. The Pan African Medical Journal, 21, 123.
http://dx.doi.org/10.11604/pamj.2015.21.123.6001

[13]   Ramanampamonjy, R.M., Randria, M.J.D., Razafimahefa, S.H., et al. (2007) Séroprévalence de l’infection due à Helicobacter pylori dans un échantillon de population malgache. Bulletin de la Société de pathologie exotique, 100, 57-60.

[14]   Konate, A., Diarra, M., Soucko-Diarra, A., et al. (2007) Gastrites chroniques à l’ère d’Helicobacter pylori au Mali. Acta Endoscopica, 37, 315-320.
http://dx.doi.org/10.1007/BF02961921

[15]   Lamarque, D., Burucoa, C., Courillon-Mallet, A., et al. (2012) Révision des recommandations francaises sur la prise en charge de l’infection par Helicobacter pylori. Hépato-Gastro, 19, 475-502.

[16]   Malfertheiner, P., Megraud, F., O’Morain, C.A., et al. (2012) Management of Helicobacter pylori Infection—The Maastricht IV/Florence Consensus Report. Gut, 61, 646-664.
http://dx.doi.org/10.1136/gutjnl-2012-302084

[17]   Ma, H.-J. and Wang, J.-L. (2013) Quadruple Therapy for Eradication of Helicobacter pylori. World Journal of Gastroenterology, 19, 931-935.
http://dx.doi.org/10.3748/wjg.v19.i6.931

[18]   Pan, K.F., Zhang, L., Gerhard, M., et al. (2016) A Large Randomised Controlled Intervention Trial to Prevent Gastric Cancer by Eradication of Helicobacter pylori in Linqu County, China: Baseline Results and Factors Affecting the Eradication. Gut, 65, 9-18.

[19]   Seyedmajidi, S., Mirsattari, D., Zojaji, H., et al. (2013) Penbactam for Helicobacter pylori Eradication: A Randomised Comparison of Quadruple and Triple Treatment Schedules in an Iranian Population. Arab Journal of Gastroenterology, 14, 1-5.
http://dx.doi.org/10.1016/j.ajg.2012.12.004

[20]   (1999) Conférence de consensus sur Helicobacter pylori. Revision des conclusions et recommandations du groupe de travail. Gastroenterologie Clinique et Biologique, 23, C95-C104.

[21]   Lamouliatte, H., Megraud, F., Delchier, J.C., et al. (2003) Second Line Treatment for Failure to Eradicate Helicobacter pylori: A Randomized Trial Comparing Four Treatment Strategies. Alimentary Pharmacology & Therapeutics, 18, 791-797.
http://dx.doi.org/10.1046/j.1365-2036.2003.01759.x

[22]   Lind, T., van Zanten, S.V., Unge, P., et al. (1996) Eradication of Helicobacter pylori Using One-Week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study. Helicobacter, 1, 138-144.
http://dx.doi.org/10.1111/j.1523-5378.1996.tb00027.x

[23]   Graham, D.Y. and Fischbach, L. (2010) Helicobacter pylori Treatment in the Era of Increasing Antibiotic Resistance. Gut, 59, 1143-1153.
http://dx.doi.org/10.1136/gut.2009.192757

[24]   Kuo, C.H., Hu, H.M., Kuo, F.C., et al. (2009) Efficacy of Levofloxacin-Based Rescue Therapy for Helicobacter pylori Infection after Standard Triple Therapy: A Randomized Controlled Trial. Journal of Antimicrobial Chemotherapy, 63, 1017-1024.
http://dx.doi.org/10.1093/jac/dkp034

[25]   Tzathas, C., Triantafyllou, K., Mallas, E., et al. (2008) Effect of Helicobacter pylori Eradication and Antisecretory Maintenance Therapy on Peptic Ulcer Recurrence in Cirrhotic Patients: A Prospective, Cohort 2-Year Follow-Up Study. Journal of Clinical Gastroenterology, 42, 744-749.
http://dx.doi.org/10.1097/MCG.0b013e3180381571

[26]   Fuccio, L., Minardi, M.E., Zagari, R.M., et al. (2007) Meta-Analysis: Duration of First-Line Proton-Pump Inhibitor Based Triple Therapy for Helicobacter pylori Eradication. Annals of Internal Medicine, 147, 553-562.
http://dx.doi.org/10.7326/0003-4819-147-8-200710160-00008

[27]   Graham, D.Y., Malaty, H.M., Evans, D.G., et al. (1991) Epidemiology of Helicobacter pylori in an Asymptomatic Population in the United States. Gastroenterology, 100, 1495-1501.

[28]   Replogle, M.L., Glasser, S.L., Hiatt, R.A. and Parsonnet, J. (1995) Biologic Sex as a Risk Factor for Helicobacter pylori Infection in Healthy Young Adults. American Journal of Epidemiology, 142, 856-863.

[29]   Stolte, M. and Meining, A. (2001) The Updated Sydney System: Classification and Grading of Gastritis as the Basis of Diagnosis and Treatment. Canadian Journal of Gastroenterology, 5, 591-598.

[30]   Attia, K.A., N’Dri Yoman, T., Diomandé, M.I., et al. (2001) Aspects cliniques, endoscopiques et histologiques des gastrites chroniques à Helicobacter pylori en Cote d’Ivoire: Etude de 102 patients. Bulletin de la Société de pathologie exotique, 94, 5-8.

[31]   Graham, D.Y. (1998) Antibiotic Resistance in Helicobacter pylori: Implications for Therapy. Gastroenterology, 115, 1272-1277.
http://dx.doi.org/10.1016/S0016-5085(98)70100-3

[32]   Megraud, F. and Lamouliatte, H. (2003) Review Article: The Treatment of Refractory Helicobacter pylori Infection. Alimentary Pharmacology & Therapeutics, 17, 1333-1343.
http://dx.doi.org/10.1046/j.1365-2036.2003.01592.x

[33]   Raymond, J., Lamarque, D., Kalach, N., et al. (2010) High Level of Antimicrobial Resistance in French Helicobacter pylori Isolates. Helicobacter, 15, 21-27.
http://dx.doi.org/10.1111/j.1523-5378.2009.00737.x

[34]   Romano, M., Iovene, M.R., Russo, M.I., et al. (2008) Failure of First-Line Eradication Treatment Significantly Increases Prevalence of Antimicrobial-Resistant Helicobacter pylori Clinical Isolates. Journal of Clinical Pathology, 61, 1112-1115.
http://dx.doi.org/10.1136/jcp.2008.060392

[35]   Horiki, N., Omata, F., Uemura, M., et al. (2009) Annual Change of Primary Resistance to Clarithromycin among Helicobacter pylori Isolates from1996 through 2008 in Japan. Helicobacter, 14, 86-90.

[36]   Hunt, R.H., Xiao, S.D., Megraud, F., et al. (2011) Helicobacter pylori in Developing Countries. World Gastroenterology Organisation Global Guideline. Journal of Gastrointestinal and Liver Diseases, 20, 299-304.

[37]   Seck, A., Mbengue, M., Gassama-Sow, A., et al. (2009) Antibiotic Susceptibility of Helicobacter pylori Isolates in Dakar, Senegal. The Journal of Infection in Developing Countries, 3, 137-140.
http://dx.doi.org/10.3855/jidc.512

[38]   Lee, J.H., Shin, J.H., Roe, I.H., et al. (2005) Impact of Clarithromycin Resistance on Eradication of Helicobacter pylori in Infected Adults. Antimicrobial Agents and Chemotherapy, 49, 1600-1603.
http://dx.doi.org/10.1128/AAC.49.4.1600-1603.2005

[39]   De Francesco, V., Margiotta, M., Zullo, A., et al. (2006) Clarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori. Annals of Internal Medicine, 144, 94-100.
http://dx.doi.org/10.7326/0003-4819-144-2-200601170-00006

[40]   Vaira, D., Zullo, A., Vakil, N., et al. (2007) Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: A Randomized Trial. Annals of Internal Medicine, 146, 556-563.
http://dx.doi.org/10.7326/0003-4819-146-8-200704170-00006

[41]   Wu, D.C., Hsu, P.I., Wu, J.Y., et al. (2010) Sequential and Concomitant Therapy with Four Drugs Is Equally Effective for Eradication of H pylori Infection. Clinical Gastroenterology and Hepatology, 8, 36-41.
http://dx.doi.org/10.1016/j.cgh.2009.09.030

[42]   Malfertheiner, P., Bazzoli, F., Delchier, J.C., et al. (2011) Helicobacter pylori Eradication with a Capsule Containing Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given with Omeprazole versus Clarithromycin-Based Triple Therapy: A Randomised, Open-Label, Non-Inferiority, Phase 3 Trial. The Lancet, 377, 905-913.
http://dx.doi.org/10.1016/S0140-6736(11)60020-2

[43]   Laine, L., Hunt, R., El-Zimaity, H., et al. (2003) Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given with Omeprazole versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. American Journal of Gastroenterology, 98, 562-567.
http://dx.doi.org/10.1111/j.1572-0241.2003.t01-1-07288.x

[44]   Luther, J., Higgins, P.D., Schoenfeld, P.S., et al. (2010) Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability. American Journal of Gastroenterology, 105, 65-73.
http://dx.doi.org/10.1038/ajg.2009.508

 
 
Top